Cabaletta Bio Inc (CABA)
10.17
+0.24
(+2.42%)
USD |
NASDAQ |
May 31, 16:00
10.17
0.00 (0.00%)
After-Hours: 20:00
Cabaletta Bio Cash from Operations (Quarterly): -23.99M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -23.99M |
| December 31, 2023 | -16.45M |
| September 30, 2023 | -12.60M |
| June 30, 2023 | -11.89M |
| March 31, 2023 | -12.61M |
| December 31, 2022 | -12.13M |
| September 30, 2022 | -9.914M |
| June 30, 2022 | -11.53M |
| March 31, 2022 | -12.81M |
| December 31, 2021 | -10.52M |
| September 30, 2021 | -8.344M |
| Date | Value |
|---|---|
| June 30, 2021 | -6.58M |
| March 31, 2021 | -8.67M |
| December 31, 2020 | -9.173M |
| September 30, 2020 | -5.024M |
| June 30, 2020 | -7.642M |
| March 31, 2020 | -4.931M |
| December 31, 2019 | -7.883M |
| September 30, 2019 | -2.076M |
| June 30, 2019 | -3.821M |
| March 31, 2019 | -2.265M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-23.99M
Minimum
Mar 2024
-2.076M
Maximum
Sep 2019
-9.929M
Average
-9.544M
Median
Cash from Operations (Quarterly) Benchmarks
| Editas Medicine Inc | -49.87M |
| ACADIA Pharmaceuticals Inc | 29.08M |
| Alnylam Pharmaceuticals Inc | -81.52M |
| Regeneron Pharmaceuticals Inc | 1.512B |
| Vertex Pharmaceuticals Inc | 1.307B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.812M |
| Cash from Financing (Quarterly) | 6.855M |
| Free Cash Flow | -66.05M |
| Free Cash Flow Per Share (Quarterly) | -0.503 |
| Free Cash Flow Yield | -14.33% |